Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO Korea 2016: SillaJen On Maximizing Value Of Pexa-Vec

This article was originally published in PharmAsia News

Executive Summary

South Korea's SillaJen, which has ambitions to launch its oncolytic virus-based immunotherapy Pexa-Vec in global markets in the next few years, has unveiled progress of its global Phase III study and the company's global strategy during the recent BIO Korea 2016 in Seoul.


Related Content

Monumental Year Ahead For Korean Pharmas As New US Approvals Eyed
Samsung BioLogics IPO May Set Tone For Korean Biopharma Investors


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts